Staphylococcus aureus can cause numerous disease processes, and management varies with pathology and severity. It is important for the general pediatrician to identify factors that increase a patient's risk of developing S aureus infection to ensure appropriate treatment.
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ABBREVIATIONS

CASES
1) A 7-month-old boy, previously healthy, is seen in the emergency department with a 1-day history of rash, which had the initial appearance of a sunburn. Involved areas are now peeling. His parents describe him as being very fussy and having decreased number and volume of wet diapers. On physical examination he is afebrile, with a temperature of 99.5°F (37.5°C), heart rate of 164 beats/min, respiratory rate of 32 breaths/min, blood pressure of 72/46 mm Hg, and pulse oxygen saturation of 99% on room air. He has numerous bullae over his body and a positive Nikolsky sign. Staphylococcal scalded skin syndrome (SSSS). 2) A 12-year-old boy hospitalized for inflammatory bowel disease management has a central venous line for total parenteral nutrition. He suddenly develops a new fever (102.0 o F [38.9 o C]), is shivering, and complains of being "cold." Physical examination reveals a toxic-appearing boy who is febrile to 103.1°F (39.5°C) and has a heart rate of 126 beats/min, respiratory rate of 24 breath/min, blood pressure of 90/40 mm Hg, and pulse oxygen saturation of 98% on room air. The central line insertion site is without erythema or drainage. His examination reveals a new cardiac systolic murmur, tachycardia, and poor perfusion. Blood cultures are obtained from his central line as well as a peripheral venipuncture, and he is given intravenous (IV) antibiotics due to his toxic clinical appearance. Within 24 hours, blood cultures grow S aureus. The central line is removed and his antibiotics are appropriately tailored once antibiotic susceptibilities are available on the bacteria. However, he continues to have positive blood cultures for 5 days after removal of the central line and appropriate antibiotic therapy. Due to his new cardiac murmur and the persistence of positive blood cultures, an echocardiogram is performed and a large thrombus is detected on his tricuspid valve. Bacteremia and infective endocarditis (IE) with a central line.
3) A 3-year-old toddler, previously healthy with normal growth and development, is seen for an urgent visit for a chief concern of limping for 2 days. He is usually a very active child and plays and runs around the house in the morning with his siblings. This morning he woke up and refused to walk or play. In the clinic, he is febrile to 101.5°F (38.6°C), heart rate of 130 beats/min, respiratory rate of 38 breaths/min, blood pressure of 80/56 mm Hg, and pulse oxygen saturation of 97%. On physical examination, the child is keeping his right leg abducted, flexed, and externally rotated. He refuses to move it from this position and does not allow you to move it passively. Imaging is obtained and shows an effusion of the hip. He is diagnosed as having septic arthritis and is taken to surgery.
Osteoarticular infection
BACTERIAL VIRULENCE FACTORS
To understand the basic hardiness and virulence of this bacterium, a review of the structure, extracellular products, and genetic elements is paramount. (1) S aureus is a gram-positive bacterium that appears in clusters on Gram-stain. (1) It is catalase positive and, unlike other staphylococcal species, coagulase positive. (1) There are several methods to identify S aureus, eg, polymerase chain reaction and peptide nucleic acid fluorescence in situ hybridization, although the best known and most used is the bacterial culture. (2) S aureus has a variety of virulence factors that, singly and in combination, can result in severe infection. Catalase, produced by S aureus, is an enzyme that allows intracellular survival of this bacterium by breaking down hydrogen peroxide, a host defense mechanism. (3) Surface proteins of S aureus include coagulase (the catalyst that generates fibrin from fibrinogen) and clumping factors (which cause clotting). (1) Toxins and extracellular substances include hemolysins (which destroy erythrocytes), leukocidins (which cause skin necrosis), and exfoliative toxin and enterotoxins B and C (which propagate the systemic inflammatory response). (1) Panton-Valentine leukocidin is a toxin that can do all the above. (4) These virulence factors allow S aureus to cause the variety of clinical syndromes for which this bacterium is known, including the development of abscesses.
S aureus can acquire new genetic elements. (1) Local environmental stressors, such as low pH, low oxygen, poor availability of nutrients, extremes in temperatures, and antibiotic use, may force altered genetic expression through regulatory mechanisms. (1) In total, intrinsic and acquired genetic material expands the ability of S aureus to affect the patient while surviving in harsh conditions.
RESISTANCE PATTERNS
S aureus has proved adept at developing antibiotic resistance. This is accomplished through acquisition of mobile genetic elements that transfer resistance and virulence from other bacterial species and staphylococcal strains. (1) External pressures (namely, overuse of antibiotics) can also force a previously susceptible isolate to become resistant.
The most well-known story of S aureus resistance follows the introduction of penicillin. S aureus developed resistance via production of b-lactamase, which prevents the antibiotic from binding to the penicillin-binding protein (PBP) on S aureus. This lack of binding to PBP obstructs the ability of the penicillin drug to inhibit bacterial cell wall synthesis. (1) This b-lactamase was not native to S aureus, it was acquired via a plasmid-encoded penicillinase. (1)(5)
The evolution of methicillin resistance should be familiar. Semisynthetic penicillins (the prototype being methicillin) were developed by scientists to circumvent the problem of S aureus b-lactamase resistance. However, shortly after the introduction of these compounds, some S aureus strains became methicillin resistant. Methicillin resistance was acquired via the mecA gene encoding for PBP2a, which decreases the binding affinity of antibiotics to the target bacterium. (5)(6) It is proposed that S aureus acquired the mecA gene from other staphylococcal species. (6) An ominous example of acquisition of resistance pertains to vancomycin, regarded by medical providers as a workhorse against gram-positive pathogens. Vancomycinintermediate S aureus (VISA) was identified in the 1990s. Although the resistance mechanisms of VISA are not completely understood, the result is a minimum inhibitory concentration (MIC) of vancomycin greater than or equal to 4 mg/mL to overwhelm S aureus (the usual MIC is <2 mg/mL).
(1) Vancomycin-resistant S aureus (VRSA) is defined as possessing a MIC for vancomycin that is greater than or equal to 16 mg/mL. The susceptibility of S aureus isolates to clindamycin is variable. The provider should be aware that methicillinsensitive S aureus (MSSA) and methicillin-resistant S aureus (MRSA) isolates may be intrinsically resistant to clindamycin or resistance may be inducible. The latter is suspected if there is discordance in a laboratory result: clindamycinsusceptible but erythromycin-resistant S aureus. (2) In this situation, the laboratory will conduct a procedure on the bacteria known as the D test. (2) In the case of a positive D test result (inducible clindamycin resistance), an alternate drug is used. A study from found MSSA and MRSA clindamycin-resistance rates as high as 32.7% and 90.8%, respectively. (7) In 1 study using a multihospital database in the United States from 2007 through 2011, 24,644 clinically relevant S aureus isolates were reported. Of those that had clindamycin susceptibility testing completed, 39.1% to 40.4% were clindamycin resistant (the authors did not distinguish between MRSA and MSSA). (8) Knowledge of community antibiotic resistance patterns to S aureus should guide empirical antibiotics used to treat community-acquired MRSA (CA-MRSA) and hospitalacquired MRSA. The latter is usually multidrug resistant, whereas CA-MRSA is often susceptible to clindamycin, doxycycline, and trimethoprim-sulfamethoxazole (TMP-SMX).
(2) When confronted with suspected S aureus, providers should be aware of the proportion of CA-MRSA compared with MSSA in their community, and the resistance of the prevailing S aureus strains (especially against clindamycin). This information may be obtained by contacting local infectious diseases practitioners or the director of a local facility's microbiology laboratory.
COLONIZATION AND TRANSMISSION
Staphylococcus is considered a part of normal human flora termed colonization. A common body area of S aureus colonization is the anterior nares. An estimated one-third of the human population (including the pediatric population) has asymptomatic S aureus colonization. (2)(9)(10)(11) In 2016, among kindergarten attendees in Iran, 25% were colonized with MSSA and 6% with MRSA. (12) In a prospective study of children in St Louis with community-onset S aureus skin and skin structure infections (SSSIs), more than half of the patients were colonized with 1 strain, 44% with 2 strains, and 4% with 3 strains. (13) Therefore, it is not unusual for a pediatric patient to be colonized with S aureus, and to possibly harbor more than 1 S aureus isolate.
Colonization is a risk factor for infection, and infection often occurs with the same S aureus strain that colonized the individual. In the previously cited study from St Louis, 67% of children were colonized with the same strain of S aureus that caused their SSSI. (13) In a survey of outcomes of children in the 6 months after knowledge of S aureus colonization, SSSI developed in 23% of children colonized with MRSA, 8% of children colonized with MSSA, and 7% without evidence of previous colonization. (14) Infections may not always result from the patient's colonizing S aureus strain. One prospective study determined that more than half of the S aureus SSSIs in children were caused by a strain with which the child was not colonized. (15) Asymptomatic colonized individuals may spread the organism to others. (11) Sources for noncolonizing strains include household contacts. However, 1 study demonstrated that less than half of the strains responsible for the infection were the same strain with which the patient or household contact was colonized. (2)(13)
SUPPURATIVE ILLNESSES
The pathologic development of the following suppurative infectious syndromes are similar regardless of causative bacterial agent. The discussion of illnesses later herein is summarized in Table 1 . The provider should allow the severity of disease and the suspicion of MRSA to guide the choice of empirical antibiotics.
Skin and Skin Structure Infections
One of the more common manifestations of S aureus is SSSI (previously named skin and soft tissue infection). (16)(17) Although 1 study reported an increasing rate of hospitalizations for pediatric SSSI over a 10-year period, only 20% of these were secondary to S aureus, including 10% from CA-MRSA. (18) Methicillin-resistant S aureus SSSI seems to be more prevalent in the late spring to late summer months. (18) (19) Thus, the provider should be aware that only a minority of SSSIs requiring hospitalization are caused by S aureus and that SSSIs secondary to MRSA may have a seasonal propensity.
In addition to nonintact skin being a risk factor for SSSI, an additional risk is seen in patients with atopic dermatitis. Atopic dermatitis is an inflammatory disorder of the skin, which Appropriate treatment depends on whether the suspected or confirmed pathogen is MSSA or MRSA. Antibiotic treatment for MSSA includes a b-lactamase-resistant penicillin or, if allergic, a first-generation cephalosporin. (2)(21) If there is concern for MRSA (given community prevalence), TMP-SMX, doxycycline, clindamycin, or linezolid can be used for MRSA treatment. (2)(21) Purulent cellulitis should be treated empirically for MRSA until cultures result to guide treatment; duration is 5 to 10 days. (21) Trimethoprim-sulfamethoxazole should never be used as empirical monotherapy for cellulitis given the historically poor treatment of Streptococcus pyogenes. 
Infective Endocarditis. Infective endocarditis is not as common in the pediatric population as in the adult population. In incidence studies, more than half of the cases of pediatric IE possess an underlying cardiac condition. (29) (30) The incidence of IE has not changed appreciably between the early 2000s and the 2010s, (0.41-0.43 per 100,000 children). The most common responsible organism was S aureus, accounting for 24% to 36% of IE. (26) (29)(30) So although IE is not common in pediatrics, the clinician should be aware that S aureus accounts for onethird of these infections.
For S aureus IE, vancomycin plus a BLRBL is the treatment of choice until guided by susceptibility results. For MSSA, a BLRBL (eg, nafcillin, oxacillin, or cefazolin) is the treatment of choice with the option of adding gentamicin for synergy for the first 3 to 5 days of treatment. Pneumonia. Compared with other bacteria, S aureus is a less common cause of pneumonia (community and hospital acquired). Active population surveillance for communityacquired pneumonia at 3 pediatric hospitals in the United States found that S aureus accounted for 1% of communityacquired pneumonia requiring hospitalizations. (37) Necrotizing pneumonia (destruction of lung parenchyma with vascular changes) is an uncommon but severe complication of community-acquired pneumonia. A retrospective study in Poland noted that necrotizing pneumonia in children accounted for 3% of all hospital admissions for pneumonia from 2008 to 2013. (38) S aureus is 1 of the recognized causative organisms of necrotizing pneumonia and accounts for 6% to 32% of all necrotizing pneumonia. (38)(39) A large proportion of S aureus isolates responsible for necrotizing pneumonia possess the gene for PantonValentine leukocidin (previously described in this review as a virulence factor). (39) Overall, S aureus is an uncommon cause of pneumonia, but the clinician should be aware of the ability of some strains of S aureus to cause necrotizing pneumonia.
The empirical treatment of pneumonia suspected to be from S aureus depends on severity of presentation and prevalence of MRSA. Pneumonia from MSSA should be treated with a BLRBL. Vancomycin remains the preferred empirical antibiotic for MRSA-suspected severe pneumonia, but it has relatively poor lung tissue penetration. Initial empirical antibiotic treatment for osteoarticular infections should be administered IV. Empirical therapy for presumed or proven MSSA involvement should be nafcillin or oxacillin, although cefazolin may be used given that dosing is convenient at every 8 hours compared with every 6 hours for the semisynthetic penicillins. The empirical treatment for osteomyelitis and septic arthritis is vancomycin when CA-MRSA rates are greater than 10%. (2)(4) Alternatives include clindamycin (if clindamycin resistance is low and there is no associated bacteremia) and linezolid. (4)(21) The minimum treatment duration is 3 to 4 weeks for septic arthritis and 4 to 6 weeks for osteomyelitis, predicated on clinical response and normalization of inflammatory markers, particularly the erythrocyte sedimentation rate (ESR). (4)(21) The decision on final therapy, including drug and mode of delivery (IV versus oral), should include discussion on whether the pathogen has been identified, whether the treatment course was complicated by poor clinical or microbiologic response (such as prolonged secondary bacteremia), compliance of patient and family with possible oral regimen, and availability of medical facilities for families to seek care for unexpected complications. Early involvement of an orthopedic surgeon is important in both diagnosis and treatment of osteoarticular infections. Because this illness is due to ingestion of preformed toxin, antibiotics are unnecessary, and the patient needs supportive care only. (1) Staphylococcal Scalded Skin Syndrome Some strains of S aureus produce exfoliative toxins that are implicated in SSSS. (1) The toxins spread hematogenously and result in fever, erythema, and destruction of the proteins that are responsible for maintaining a crucial connection in the skin. (1) The toxin cleaves the desmoglein 1 glycoprotein in the stratum corneum, leading to bullae. These will rupture and result in denuded skin. Some of these patients have a positive Nikolsky sign. Staphylococcal scalded skin syndrome is a clinical diagnosis, but S aureus may be cultured from an affected site. (1) Viable S aureus can continue to produce exfoliative toxins and propagate the disease. Antibiotics should be given for SSSS; this will not reverse the destruction of the skin but can prevent further damage. (1) The treatment of choice is an IV BLRBL or vancomycin if CA-MRSA prevalence is high. (2) (22) It may help to regard and manage patients with SSSS as if they possess severe partial-thickness burns, given possible high insensible losses due to capillary leak and damaged skin barrier.
Toxic Shock Syndrome
Toxic shock syndrome (TSS) is mediated by TSS toxin 1, or the combination of staphylococcal enterotoxin B and staphylococcal enterotoxin C toxins. The signs and symptoms include rapid onset of fever, a widespread rash resembling a sunburn (erythroderma), hypotension, and multisystem organ dysfunction. (1)(2) Risk factors for TSS include the presence of a strain able to produce the aforementioned toxin(s). The initial site of entry or infection may be unremarkable because TSS toxin 1 has the ability to dampen the local inflammatory response. (1) The mucous membranes (vagina, nasopharyngeal), wound (if present), and blood should be cultured as part of the diagnostic evaluation. (1) The main focus of treatment includes management of hypovolemic shock (given high insensible losses due to capillary leak), respiratory failure, and infection.
Intravenous antibiotics should be initiated empirically to treat S aureus and to inhibit protein synthesis to prevent further toxin from being produced. (1)(2) This antibiotic regimen includes an IV BLRBL and clindamycin (for disruption of protein synthesis, ie, toxin production), and often vancomycin given concern for MRSA. Once culture results are available, the antibiotics should be tailored to susceptibilities, and treatment duration is 10 to 14 days. (2) If there is a localized infection that is the inciting event, treatment should include adequate incision and drainage, and removal of a foreign body if present. (2)
ANTIMICROBIALS
The choice of antibiotic for infections suspected or confirmed to be secondary to S aureus depends on several factors. First is the severity of the presenting illness. Inadequate treatment may not be immediately detrimental for a patient presenting in the office with cellulitis but will have dire consequences in a patient with sepsis. Another factor is the rate of MRSA present in the community, which drives the use of vancomycin or other MRSA-active agents for empirical treatment. Bactericidal agents are always preferred over bacteriostatic antibiotics, although b-lactam allergies or the presence of MRSA may not always allow the use of bactericidal agents. Table 2 summarizes the following  antibiotics. For MSSA, nafcillin, oxacillin, and a first-generation cephalosporin (cefazolin) are first-line parenteral antibiotics. The mechanism of action of b-lactams (penicillins and cephalosporins) is inhibition of bacterial cell wall synthesis. bLactams bind to PBPs, which prevents a new disaccharide from joining the peptidoglycan polymer, therefore blocking the formation of the peptidoglycan layer that surrounds the bacterium. The BLRBLs are bactericidal against S aureus and are superior to vancomycin, which has a slow kill time against S aureus, making it, in effect, bacteriostatic. (21) Adverse effects of BLRBLs include bone marrow suppression and interstitial nephritis. Overall, a BLRBL should be used for MSSA infections. Oral conversion to cephalexin is possible when using these empirical agents.
For MRSA, vancomycin is usually the first consideration in patients with serious infections, including bacteremia and endovascular infections. Vancomycin is a glycopeptide that inhibits the synthesis of the bacterial cell wall. Vancomycin binds to a subunit of the peptide side chain (D-alanyl-D-alanine). Owing to its large molecular size, vancomycin occupies a sizable area and, thus, prevents further synthesis of the peptidoglycan polymer around the bacterium. For clinical use, vancomycin is often considered bacteriostatic. Although the minimum bactericidal concentration is similar to the MIC of vancomycin against S aureus, the rate of S aureus killing is slower for vancomycin compared with other antistaphylococcal antibiotics. (49) Dosing of vancomycin is based on the age of the patient, severity of infection, and known or developing renal insufficiency. Therapeutic drug monitoring is usually conducted with serum trough levels (obtained by venipuncture 1 hour before dose). For invasive and severe infections, the goal trough level for vancomycin is 15 to 20 mg/mL. (21) When the practitioner is empirically using vancomycin, de-escalation to an oral agent may be difficult if bacterial cultures were not obtained before initiation of therapy or remain sterile.
Other antibiotics used for MRSA as well as MSSA infections (usually with less severe clinical presentations) include clindamycin, linezolid, doxycycline, and TMP-SMX.
Clindamycin is an attractive option for practitioners who want to use an agent with generally effective treatment of MSSA and MRSA. The mechanism of action of clindamycin is inhibition of protein synthesis by binding the 50S ribosomal subunit preventing transpeptidation. Advantages of clindamycin include excellent tissue penetration (bone, abscess) and the high bioavailability of the oral drug. However, clindamycin is a bacteriostatic drug against S aureus and may not have activity against all isolates of MSSA or MRSA. These 2 reasons should be recalled if the provider is facing a patient with poor clinical response while taking empirical clindamycin. Furthermore, clindamycin has poor penetration into cerebrospinal fluid and should not be used in primary bacteremia because it does not have this Food and Drug Administration (FDA) indication. (21) The most common adverse effect of clindamycin is diarrhea. (21)(50) The practitioner should balance the benefits and risks of using clindamycin when confronted with a suspected S aureus infection. Linezolid is often used in the ambulatory setting as an oral alternative to IV vancomycin, particularly for SSSI and pneumonia. (21) The mechanism of action is inhibition of protein synthesis by binding the bacterial 50S ribosomal subunit, which prevents the assembly of the entire initiation complex. Linezolid is bacteriostatic against S aureus. (50) Bioavailability is almost 100%. (50) Adverse effects include reversible bone marrow suppression (thrombocytopenia, neutropenia, and/or anemia), irreversible neuropathy, gastrointestinal upset, lactic acidosis, and hyperglycemia. (21) (50) The benefit of linezolid is ease of transition between parenteral to oral administration and its effectiveness against MRSA.
Doxycycline is an excellent choice for outpatient treatment for SSSI and is active against MRSA. Doxycycline is a tetracycline that is bacteriostatic at lower concentrations and bactericidal at higher concentrations. (21)(50) The mechanism of action is inhibiting protein synthesis by binding the 30S ribosomal subunit preventing transfer RNA from binding. Adverse effects include gastrointestinal upset (nausea and vomiting) and phototoxicity. (50) It is prudent to avoid prolonged courses (>21 days) in young children given concern for discoloration of developing tooth enamel.
Outpatient treatment with TMP-SMX is an attractive option for MRSA. (21) It is bacteriostatic. The mechanism of action is a blockage of metabolic pathways that are essential for bacterial DNA synthesis and, therefore, growth. The sulfonamide component can displace bilirubin from albumin. This displacement increases the serum level of unconjugated bilirubin and elevates the risk of bilirubin-induced neurologic dysfunction. (21) Although FDA labeling cautions against use in infants younger than 2 months, it may be used safely in full-term infants as early as 2 weeks after birth as physiologic jaundice is resolving. (1) For those with renal disease there is an increased risk of hyperkalemia from use of this medication. (21) Often, TMP-SMX is used in the outpatient setting, but the practitioner should bear in mind that it has poor activity against S pyogenes, often in the differential diagnosis for SSSIs.
DECOLONIZATION
The goal of decolonization is the reduction of the infectious burden of a particular organism from a specific body site. In the general population, 20% have persistent colonization with S aureus, 60% are intermittently colonized, and 20% are never colonized. (1) Decolonization of patients with persistent or intermittent colonization may be desirable in situations involving recurrent SSSIs, atopic dermatitis, or those anticipating surgeries with implantable or prosthetic materials (such as prosthetic joints).
A decolonization program should include considering the body area of interest, the medication, the duration of the program, and the number of household members needed to treat to reduce transmission. The most common area of S aureus colonization is the anterior nares. There is no evidence that decolonization has sustained effects. (51) A Cochrane review regarding decolonization found 188 articles regarding effectiveness of S aureus decolonization. Only 2 studies were deemed eligible for analysis, and both were inconclusive: 1) mupirocin versus placebo and 2) anerdian versus no treatment. (51)(52)(53) Another publication that reviewed 19 articles suggested a reduction in surgical site infections after decolonization. (9) These decolonization regimens varied and included mupirocin alone, or mupirocin with either chlorhexidine or triclosan. (9) Not all the studies had statistically significant reductions in surgical site infections. (9) Despite the lack of evidential support, decolonization can be considered in certain circumstances, as described previously herein. For patients with atopic dermatitis or recurrent SSSI, decolonization can be considered if recurrence persists despite excellent hand hygiene and wound care. 
Summary
• Based on observational and epidemiologic studies, approximately one-third of the population is colonized with Staphylococcus aureus, and colonization of the individual and/or household members is a risk factor for S aureus infection.
• From evidence-based guidelines, empirical treatment for nonlife-threatening infections suspected to be from S aureus should include methicillin-sensitive S aureus (MSSA) treatment, ideally a b-lactamase-resistant b-lactam (BLRBL). Methicillin-resistant S aureus (MRSA) treatment may be included (either with a second drug or more often as clindamycin monotherapy) in geographic areas with high rates of community-acquired MRSA.
• From published clinical guidelines and expert opinion, empirical treatment for life-threatening and invasive S aureus infections should cover both MSSA and MRSA. This includes a parenteral BLRBL (for MSSA) and vancomycin (for MRSA) while awaiting culture results and susceptibilities.
• From evidence-based guidelines, the treatment of staphylococcal scalded skin syndrome includes parenteral antibiotics and fluid and electrolyte management.
• Evidence-based guidelines recommend that the treatment of toxic shock syndrome due to S aureus includes drainage of the nidus of infection, antibiotics targeted to inhibiting bacterial cell wall synthesis (such as nafcillin/oxacillin or vancomycin), and inhibiting protein synthesis (such as clindamycin).
• On the basis of Cochrane review and expert opinion, decolonization practices have little evidential support. These practices may be used if the patient experiences recurrent skin and skin structure infections despite optimization of hand hygiene and wound care. If decolonization is recommended, all members in the household should also undergo this process.
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